![Jean Claude Tardif, MD, FACC](/-/media/Non-Clinical/Images/System-Images/Profile-Images/T/Tardif-Jean-Claude.jpg)
General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Amarin(SIGNIFICANT), HLS Therapeutics(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), DalCor Pharmaceuticals(SIGNIFICANT), Pharmascience(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: DalCor Pharmaceuticals(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Amarin(SIGNIFICANT), Esperion(SIGNIFICANT), Astra-Zeneca(SIGNIFICANT), Ceapro(SIGNIFICANT), DalCor Pharmaceuticals(SIGNIFICANT), Ionis(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Pfizer(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT)